Novartis AG (LTS:0QM7) Cyclically Adjusted Book per Share: CHF0.00 (As of Mar. 2026)


What is Novartis AG Cyclically Adjusted Book per Share?

Novartis AG LTS:0QM7 81 Cyclically Adjusted Book per Share is CHF0.00 as of Mar. 2026. GuruFocus rates LTS:0QM7 with a GF Score™ of 81/100. The stock has 7 warning signs investors should review.

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2026 was CHF14.050. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -5.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -3.20% per year. And the median was 2.70% per year.

As of today (2026-07-12), Novartis AG's current stock price is CHF0.00. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was CHF0.00. Novartis AG's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Novartis AG  (LTS:0QM7) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms


Novartis AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0QM7 vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.05/108.0600*108.0600
=14.050

Current CPI (Mar. 2026) = 108.0600.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201606 29.499 100.088 31.849
201609 30.720 99.604 33.328
201612 32.132 99.380 34.939
201703 28.613 100.040 30.907
201706 28.891 100.285 31.131
201709 29.706 100.254 32.019
201712 31.588 100.213 34.061
201803 28.917 100.836 30.989
201806 32.753 101.435 34.892
201809 32.670 101.246 34.869
201812 33.739 100.906 36.131
201903 20.343 101.571 21.643
201906 22.170 102.044 23.477
201909 22.975 101.396 24.485
201912 23.628 101.063 25.264
202003 21.305 101.048 22.784
202006 22.218 100.743 23.832
202009 21.654 100.585 23.263
202012 22.015 100.241 23.732
202103 20.740 100.800 22.234
202106 21.727 101.352 23.165
202109 23.242 101.533 24.736
202112 27.608 101.776 29.313
202203 25.568 103.205 26.771
202206 27.612 104.783 28.476
202209 27.154 104.835 27.989
202212 25.618 104.666 26.449
202303 22.327 106.245 22.708
202306 21.633 106.576 21.934
202309 15.909 106.570 16.132
202312 18.701 106.461 18.982
202403 16.337 107.355 16.444
202406 17.285 107.991 17.296
202409 17.006 107.468 17.100
202412 18.198 107.128 18.356
202503 15.710 107.722 15.759
202506 15.821 108.075 15.819
202509 16.354 107.710 16.407
202512 17.035 107.200 17.172
202603 14.050 108.060 14.050

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of CHF0.00 mean?
Novartis AG (LTS:0QM7) has a Cyclically Adjusted Book per Share of CHF0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted Book per Share too high?
Novartis AG's current Cyclically Adjusted Book per Share is CHF0.00. Overall, Novartis AG has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted Book per Share of CHF0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted Book per Share is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (LTS:0QM7) has a current Cyclically Adjusted Book per Share of CHF0.00. The current Cyclically Adjusted Book per Share is CHF0.00. Novartis AG's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novartis AG (LTS:0QM7), the current Cyclically Adjusted Book per Share is CHF0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.